All In Biotech

Drug Trial Radar · NCT05922878

Study of ALTO-300 in MDD

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

325

Planned (sponsor's estimate)

Start

Jun 8, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Alto NeuroscienceIndustry
Sponsor type
Industry
First posted
Jun 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Conditions

  • Major Depressive Disorder

Interventions

  • ALTO-300Drug

    ALTO-300 capsule QD

  • PlaceboDrug

    Placebo capsule QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).Time frame: Change over time for up to week 6

Locations

75 sites in 1 country. Site status is shown where the registry gives one.

  • Site 200

    Phoenix, Arizona · Recruiting

  • Site 189

    Phoenix, Arizona · Withdrawn

  • Site 187

    Yuma, Arizona · Active not recruiting

  • Site 193

    Rogers, Arkansas · Recruiting

  • Site 218

    Bellflower, California · Recruiting

  • Site 318

    Carlsbad, California · Active not recruiting

  • Site 217

    Glendale, California · Active not recruiting

  • Site 335

    Lafayette, California · Recruiting

  • Site 335

    Lafayette, California · Recruiting

  • Site 209

    Los Angeles, California · Active not recruiting

  • Site 219

    Mather, California · Recruiting

  • Site 194

    Mission Viejo, California · Terminated

  • Site 267

    Moorpark, California · Recruiting

  • Site 197

    Temecula, California · Recruiting

  • Site 203

    Colorado Springs, Colorado · Active not recruiting

  • Site 343

    Denver, Colorado · Recruiting

  • Site 345

    Evergreen, Colorado · Active not recruiting

  • Site 349

    Evergreen, Colorado · Active not recruiting

  • Site 214

    Norwalk, Connecticut · Withdrawn

  • Site 159

    Clermont, Florida · Terminated

  • Site 225

    Miami Gardens, Florida · Active not recruiting

  • Site 190

    Miami Lakes, Florida · Active not recruiting

  • Site 161

    Okeechobee, Florida · Active not recruiting

  • Site 221

    Tampa, Florida · Recruiting

  • Site 220

    West Palm Beach, Florida · Active not recruiting

  • Site 238

    Fayetteville, Georgia · Recruiting

  • Site 224

    Savannah, Georgia · Active not recruiting

  • Site 208

    Snellville, Georgia · Terminated

  • Site 293

    Stone Mountain, Georgia · Not yet recruiting

  • Site 317

    Blackfoot, Idaho · Withdrawn

  • Site 119

    Boise, Idaho · Active not recruiting

  • Site 236

    Boise, Idaho · Recruiting

  • Site 310

    Chicago, Illinois · Active not recruiting

  • Site 314

    Wichita, Kansas · Active not recruiting

  • Site 201

    Marrero, Louisiana · Terminated

  • Site 198

    Monroe, Louisiana · Terminated

  • Site 288

    Worcester, Massachusetts · Recruiting

  • Site 240

    Mankato, Minnesota · Recruiting

  • Site 265

    Minneapolis, Minnesota · Recruiting

  • Site 279

    Hattiesburg, Mississippi · Withdrawn

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.